Technology directory
A directory of all technologies currently available for licensing through UCLB.
- By Keyword(s)
- By Reference No.
There are 46 items in the directory (displaying results 21 to 40)
A Surgical Kit for Hemiarthroplasty Hip/Shoulder Replacement or Refurbishment
The technology developed at UCL consists of a surgical kit that is suited for performing a hip hemiarthroplasty, in which a femoral head is fitted directly into a socket reamed into the acetabular without any permanent liner or prosthetic acetabular being implanted. This methodology will therefore alleviate the requirement for prosthetic acetebular replacement, and the associated problems of repeat surgery to implant a new prosthetic acetebular.
| Reference: | 66-021 |
|---|---|
| Availability: | Licensing |
A Revolutionary New Type of 2-Photon Microscope, that Focuses and Scans the Laser Beam in 3D Space
We have designed and built a prototype of a revolutionary new type of 2-photon microscope. Many important, yet poorly understood processes in biology, such as electrical signalling in neural circuits, are rapid and are distributed in 3D space. Such processes are impossible to monitor with conventional optical methods which are 100-fold too slow. Our new prototype laser scanner, can not only focus and scan the laser beam in 3D space, but offers a 300 fold increase to focusing time.
| Reference: | 41-006 |
|---|---|
| Availability: | Licensing |
Phenothiazine Derivatives: Treatment for Neurodegeneration
Lipid peroxidation resulting from oxidative stress is a crucial factor in the pathogenesis of many diseases, including neurodegenerative disorders, cardiovascular disease, asthma and diabetes. Phenothiazine derivatives are capable of reducing or preventing lipid peroxidation and therefore have potential therapeutic value for numerous disease states.
| Reference: | 92-009 |
|---|---|
| Availability: | Licensing and co-development |
Osteoporosis Diagnostic
This invention identifies variations at a gene which can predict whether or not a patient will respond to Bisphosphates. Approximately 40% of recipients do not respond to Bisphosphonate treatment. The identification of non-responding individuals holds the potential to facilitate patients receiving a more appropriate course of treatment. The total world market for osteoporosis drugs surpassed an estimated £6.35 billion in 2006, and we believe that the market for a predictive assay of this type is extremely large. It is our proposal that all patients about to start any oral Bisphosphates treatment for osteoporosis should be tested to demonstrate their ability to respond to the treatment regime.
| Reference: | 22-002 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
Drug Lifecycle Visualisation Tool – In Vivo
Somatotrangenic bioimaging is a malleable platform technology for continued, quantifiable analysis of drug therapy, metabolism or toxicity in small animals.
| Reference: | 55-002 |
|---|---|
| Availability: | Licensing or investment |
Endomagnetics - SentiMAG™, for the Staging and Treatment of Breast Cancer
The SentiMAG™ is an ultrasensitive hand-held magnetic probe which can be used in conjunction with a magnetic dye to quickly and easily locate the sentinel lymph node for biopsy in breast cancer patients.
| Reference: | 26-001 |
|---|---|
| Availability: | Investment |
Novel UCL Nanocomposite Polymer and its Unique Role in the Field of Biomedical Devices
Our novel nanocomposite polymer (NC) can uniquely achieve complete tissue and blood compatibility, unlike conventional medical polymers such as PTFE and Dacron. This offers exciting possibilities for medical device manufacturers.
| Reference: | 94-092 |
|---|---|
| Availability: | Exclusive and non exclusive licensing opportunities |
Domainex Ltd: Solutions for Drug Discovery Problems
Domainex is a UK-based contract research company with breakthrough solutions for the major bottlenecks in drug discovery - the expression of challenging proteins or of their functional domains, and the design and synthesis of novel drug candidates. Domainex is applying its unique biology and chemistry services to its own internal drug discovery pipeline.
| Reference: | 39-928 |
|---|---|
| Availability: | Commercial contract research |
Evexar - Medical Devices Designed by Surgeons for Surgeons
Evexar Medical Ltd is a recent spin-out company from UCL focused on the development, manufacture and distribution of medical devices for three core surgical divisions - hernia, vascular and general surgical - alongside a range of graduated compression stocking for the hospital and retail/consumer markets.
| Reference: | 71-001 |
|---|---|
| Availability: | Investment |
Thymosin β4 and Cardiac Progenitors: New Treatments for Heart Disease
Cardiac progenitor cells capable of differentiating into several cell types, including smooth muscle and endothelial cells, have been induced from adult heart tissue by treatment with thymosin β4. These cells will be a valuable tool in the search for drugs that promote myocardial regeneration after a heart attack, or in the treatment of heart disease.
| Reference: | 89-033 |
|---|---|
| Availability: | Licensing |
Thymosin β4 Transgenic Model: A Tool for Cardiac Research
Thymosin β4 (Tβ4) plays a key role in the development of the heart. It is the only factor shown to be involved in the development of all types of cells required for myocardial development and regeneration. Transgenic animals with altered Tβ4 expression in the heart thus represent a useful tool for cardiac research.
| Reference: | 89-033 |
|---|---|
| Availability: | Non-exclusive licensing |
KCNV2: Novel Mutation Linked to Inhibition Response Failure
A failure to inhibit responses is a major neurobehavioural deficit seen in neurological disorders such as attention deficit hyperactivity disorder, ADHD. Although a genetic etiology for this deficit has been proposed, no molecular mechanism has yet been elucidated. UCL researchers have identified the first genetic mutation linked with failure of normal response inhibition, providing an attractive target for future research and therapy for disorders such as ADHD.
| Reference: | 97-012 |
|---|---|
| Availability: | Exclusive Licensing |
Superior X-ray Imaging for Early Detection of Breast Tumours
Inventors at University College London have designed a novel custom built coded aperture system which detects the small phase shift of x-rays during imaging resulting in high resolution phase contrast images
| Reference: | 44-003 |
|---|---|
| Availability: | Licensing/collaboration opportunity |
RIMS1: Novel Target for Enhancement of Cognitive Function
Although several genes have been implicated in reduced cognitive ability, much less is known about the genetic basis of enhanced cognition. UCL researchers have identified the first genetic mutation linked with supra-normal cognition, providing an attractive target for therapeutic intervention in cases of cognitive impairment or decline.
| Reference: | 97-001 |
|---|---|
| Availability: | Exclusive Licensing |
Human Therapeutic Antibodies and Vaccine Adjuvant
Inventors from UCL have used hetero-hybridoma technology and selection by bacterial polysaccharide binding activity to generate fully human IgM monoclonal antibody clones that have activity against both bacterial and viral infection.
| Reference: | 89-028 |
|---|---|
| Availability: | Licensing opportunity |
Gene Therapy Using Non-Integrating Lentiviral Vectors
Inventors from UCL have demonstrated that stable transgene expression can be achieved in vivo using non-integrating lentiviral vectors, thereby achieving sustained gene expression but eliminating the risk of insertional mutagenesis
| Reference: | 89-029 |
|---|---|
| Availability: | Licensing opportunity |
Indicators of Therapeutic Efficacy of Remicade® (Infliximab)
UCL scientists have developed an invention to predict the therapeutic efficacy of Infliximab in patients with rheumatoid arthritis (RA). This assay could possibly extend to predict efficacy of other antibody therapies such as Humira®. Additionally, the invention can be used to determine which patients should be treated with a given antibody therapy.
| Reference: | 60-032 |
|---|---|
| Availability: | Co-development and exclusive/non-exclusive licensing |
A New Model of Attention Deficit Hyperactivity Disorder (ADHD), Screen for New Drug Treatments and Genetic Markers for ADHD
We have discovered mutant mice that offer the best known model of ADHD. We have identified a novel target that can be used to screen for new drug treatments for ADHD. We believe that we have identified for the first time the correct target for this condition.Moreover our findings suggest that agonists of the target can be developed as a novel class of drug treatments. Finding a new drug treatment for ADHD is the logical next step of our work. In parallel we have identified a genetic test that can be used to identify genetic subtypes of ADHD. Our findings identify a new target for development of novel treatments for ADHD, which would avoid concerns about the use of Ritalin to treat ADHD. More recent findings show that the target is also important for alcoholism and for bipolar disorder.
| Reference: | 37-005 |
|---|---|
| Availability: | Co-development and exclusive/non-exclusive licensing |
A Novel Luminescent Label for both Fluorescence and Chemiluminescence-Based Bioassays and Cellular Probes
We present a novel fluorescent and chemiluminescent labelling system for fluorescence and direct chemiluminescent bioassays, based on the pro-chemiluminescent properties of the API fluorescent molecule. API-labelled biomolecules are detected with the use of a developing agent, whereupon the API label is converted to a non-covalently bound and sensitive chemiluminescent substrate.
| Reference: | 60-016 |
|---|---|
| Availability: | Licensing |
A Bio-Artificial Liver Machine (BAL)
We have invented a new treatment for patients with acute liver failure. Currently the only cure for liver failure is transplantation; however this treatment is restricted by the large shortage of donor organs. Many patients die whilst waiting for a transplant. There is an urgent need for a fully functioning support device, to help the patient’s own liver to recover or to act as a bridge until a transplant is available.
| Reference: | 60-045 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
